Bristol Myers Squibb (BMS) and Immatics will develop up to seven cancer cell therapies by launching a new partnership and expanding a three-year-old collaboration inked by BMS predecessor Celgene, the ...

Bristol Myers Squibb (BMS) drug Abecma was the first FDA-approved CAR T-cell therapy for multiple myeloma, but like other drugs in its class, the treatment’s serious side effect risks limit its use to ...

As a top cancer executive at Bristol Myers Squibb, Kristen Hege oversaw development of the cell therapy that would become Abecma, the first FDA- approved treatment for multiple myeloma that’s made ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...

Bristol Myers Squibb has linked its CD19-directed CAR-T cell therapy to sustained clinical responses in people with systemic lupus erythematosus (SLE), providing further evidence that the emerging ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. Bristol Myers has agreed to buy out its ...

Bristol Myers Squibb has terminated cell therapy pacts with two biotechs amid "ongoing portfolio prioritization efforts” within the Big Pharma, one of the affected companies revealed in an SEC ...